Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0RZHYI
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
FOLR1-Mal-PEG2-Ala-Ala-Asn-PABC-Eribulin
|
|||||
| Synonyms |
FOLR1 Mal PEG2 Ala Ala Asn PABC Eribulin
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Lung cancer [ICD11:2C25]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.83
|
|||||
| Antibody Name |
Farletuzumab
|
Antibody Info | ||||
| Antigen Name |
Folate receptor alpha (FOLR1)
|
Antigen Info | ||||
| Payload Name |
Eribulin
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mal-PEG2-Ala-Ala-Asn-PABC
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.08 nM | High FOLR1 expression(FOLR1+++) | ||
| Method Description |
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
|
||||
| In Vitro Model | Ovarian endometrioid adenocarcinoma | IGROV-1 cells | CVCL_1304 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3.80 nM | Moderate FOLR1 expression(FOLR1++) | ||
| Method Description |
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
|
||||
| In Vitro Model | Lung non-small cell carcinoma | NCI-H2110 cells | CVCL_1530 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 32.00 nM | Low FOLR1 expression(FOLR1+) | ||
| Method Description |
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
|
||||
| In Vitro Model | Skin squamous cell carcinoma | A431 cells | CVCL_0037 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 100 nM | Negative FOLR1 expression(FOLR1-) | ||
| Method Description |
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
|
||||
| In Vitro Model | Osteosarcoma | SJSA-1 cells | CVCL_1697 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.